Willis-Gray MG, Dieter AA, Geller EJ. Evaluation and management of overactive bladder: strategies for optimizing care. Res Rep Urol. 2016. 8:113-22. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. J Urol. 2019 Sep. 202 (3):558-563. [QxMD MEDLINE Link]. [Full Text].
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002. 21(2):167-78. [QxMD MEDLINE Link].
Dmochowski RR. Duloxetine: a summary of published clinical experience. Rev Urol. 2004. 6 Suppl 3:S56-63. [QxMD MEDLINE Link]. [Full Text].
Wein AJ, Rackley RR. Overactive bladder: a better understanding of pathophysiology, diagnosis and management. J Urol. 2006 Mar. 175(3 Pt 2):S5-10. [QxMD MEDLINE Link].
Morrison J, Steers WD, Brading AF, et al. Neurophysiology and neuropharmacology. Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. 2nd ed. Plymouth, England: Health Publications; 2002. 86-163.
de Groat WC. The urothelium in overactive bladder: passive bystander or active participant?. Urology. 2004 Dec. 64(6 Suppl 1):7-11. [QxMD MEDLINE Link].
Andersson KE, Hedlund P. Pharmacologic perspective on the physiology of the lower urinary tract. Urology. 2002 Nov. 60(5 Suppl 1):13-20; discussion 20-1. [QxMD MEDLINE Link].
DuBeau CE. Interpreting the effect of common medical conditions on voiding dysfunction in the elderly. Urol Clin North Am. 1996 Feb. 23(1):11-8. [QxMD MEDLINE Link].
Miller SW. Management and treatment of overactive bladder in the elderly. J Am Soc Consult Pharm. 1999. 14(Suppl 4):S1-S11.
Shah D, Badlani G. Treatment of overactive bladder and incontinence in the elderly. Rev Urol. 2002. 4 Suppl 4:S38-43. [QxMD MEDLINE Link]. [Full Text].
Staskin DR. Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging. 2005. 22(12):1013-28. [QxMD MEDLINE Link].
Stoddart H, Donovan J, Whitley E, Sharp D, Harvey I. Urinary incontinence in older people in the community: a neglected problem?. Br J Gen Pract. 2001 Jul. 51(468):548-52. [QxMD MEDLINE Link]. [Full Text].
Voytas J. The role of geriatricians and family practitioners in the treatment of overactive bladder and incontinence. Rev Urol. 2002. 4 Suppl 4:S44-9. [QxMD MEDLINE Link]. [Full Text].
Cheng CL, Li JR, Lin CH, de Groat WC. Positive association of female overactive bladder symptoms and estrogen deprivation: A nationwide population-based cohort study in Taiwan. Medicine (Baltimore). 2016 Jul. 95 (28):e4107. [QxMD MEDLINE Link].
Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003 May. 20(6):327-36. [QxMD MEDLINE Link].
Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001 Jun. 87(9):760-6. [QxMD MEDLINE Link].
Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000 Jul. 6(11 Suppl):S580-90. [QxMD MEDLINE Link].
Davila GW, Neimark M. The overactive bladder: prevalence and effects on quality of life. Clin Obstet Gynecol. 2002 Mar. 45(1):173-81. [QxMD MEDLINE Link].
Szabo SM, Gooch KL, Walker DR, Johnston KM, Wagg AS. The Association Between Overactive Bladder and Falls and Fractures: A Systematic Review. Adv Ther. 2018 Nov. 35 (11):1831-1841. [QxMD MEDLINE Link]. [Full Text].
Hu TW, Wagner TH, Bentkover JD, LeBlanc K, Piancentini A, Stewart WF, et al. Estimated economic costs of overactive bladder in the United States. Urology. 2003 Jun. 61(6):1123-8. [QxMD MEDLINE Link].
Liberman JN, Hunt TL, Stewart WF, Wein A, Zhou Z, Herzog AR, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology. 2001 Jun. 57(6):1044-50. [QxMD MEDLINE Link].
Jayadevappa R, Chhatre S, Newman DK, Schwartz JS, Wein AJ. Association between overactive bladder treatment and falls among older adults. Neurourol Urodyn. 2018 May 28. [QxMD MEDLINE Link].
Bailey KL, Torigoe Y, Zhou S, et al. Overactive bladder cost of illness: Analysis of Medi-Cal claims. Presented at the International Society for Pharmacoeconomics and Outcomes Research 5th Annual International meeting,. Arlington, VA. May 21-24, 2000.
Brown JS, Vittinghoff E, Wyman JF, Stone KL, Nevitt MC, Ensrud KE, et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc. 2000 Jul. 48(7):721-5. [QxMD MEDLINE Link].
Chapple C, Kelleher C, Siddiqui E, Andrae DA, Johnson N, Payne C, et al. Validation of the Overactive Bladder-Bladder Assessment Tool (OAB-BAT): A Potential Alternative to the Standard Bladder Diary for Monitoring OAB Outcomes. Eur Urol Focus. 2021 Sep. 7 (5):1176-1183. [QxMD MEDLINE Link].
Weiss JP, Blaivas JG, Bliwise DL, Dmochowski RR, Dubeau CE, Lowe FC, et al. The evaluation and treatment of nocturia: a consensus statement. BJU Int. 2011 Jul. 108(1):6-21. [QxMD MEDLINE Link].
Nitti VW, Patel A, Karram M. Diagnosis and management of overactive bladder: A review. J Obstet Gynaecol Res. 2021 May. 47 (5):1654-1665. [QxMD MEDLINE Link]. [Full Text].
Mostafaei H, Shariat SF, Salehi-Pourmehr H, Janisch F, Mori K, Quhal F, et al. The clinical pharmacology of the medical treatment for overactive bladder in adults. Expert Rev Clin Pharmacol. 2020 Jul. 13 (7):707-720. [QxMD MEDLINE Link].
Chen LC, Kuo HC. Current management of refractory overactive bladder. Low Urin Tract Symptoms. 2020 May. 12 (2):109-116. [QxMD MEDLINE Link].
Alhasso AA, McKinlay J, Patrick K, Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006 Oct 18. CD003193. [QxMD MEDLINE Link].
Chughtai B, Clemens JQ, Thomas D, Sun T, Ghomrawi H, Sedrakyan A. Real World Performance of Sacral Neuromodulation and OnabotulinumtoxinA for Overactive Bladder: Focus on Safety and Cost. J Urol. 2020 Jan. 203 (1):179-184. [QxMD MEDLINE Link].
Burgio KL. Influence of behavior modification on overactive bladder. Urology. 2002 Nov. 60(5 Suppl 1):72-6; discussion 77. [QxMD MEDLINE Link].
Wilson PD, Berghmans B, Hagen S, et al. Adult conservative management. Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence Management. Paris, France.: Health Publications; 2005. 855-94.
Wyman JF, Fantl JA, McClish DK, Bump RC. Comparative efficacy of behavioral interventions in the management of female urinary incontinence. Continence Program for Women Research Group. Am J Obstet Gynecol. 1998 Oct. 179(4):999-1007. [QxMD MEDLINE Link].
Wyman JF, Fantl JA. Bladder training in ambulatory care management of urinary incontinence. Urol Nurs. 1991 Sep. 11(3):11-7. [QxMD MEDLINE Link].
Burgio KL, Goode PS, Locher JL, Umlauf MG, Roth DL, Richter HE, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA. 2002 Nov 13. 288(18):2293-9. [QxMD MEDLINE Link].
Cardozo L, Stanton SL, Hafner J, Allan V. Biofeedback in the treatment of detrusor instability. Br J Urol. 1978 Jun. 50(4):250-4. [QxMD MEDLINE Link].
Cardozo LD, Abrams PD, Stanton SL, Feneley RC. Idiopathic bladder instability treated by biofeedback. Br J Urol. 1978 Dec. 50(7):521-3. [QxMD MEDLINE Link].
Burgio KL, Whitehead WE, Engel BT. Urinary incontinence in the elderly. Bladder-sphincter biofeedback and toileting skills training. Ann Intern Med. 1985 Oct. 103(4):507-15. [QxMD MEDLINE Link].
Sirls ER, Killinger KA, Boura JA, Peters KM. Percutaneous Tibial Nerve Stimulation in the Office Setting: Real World Experience of Over 100 Patients. Urology. 2017 Nov 28. [QxMD MEDLINE Link].
Stewart F, Gameiro LF, El Dib R, Gameiro MO, Kapoor A, Amaro JL. Electrical stimulation with non-implanted electrodes for overactive bladder in adults. Cochrane Database Syst Rev. 2016 Dec 9. 12:CD010098. [QxMD MEDLINE Link].
Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J Urol. 2013 Jun. 189 (6):2194-201. [QxMD MEDLINE Link].
Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA. 1998 Dec 16. 280(23):1995-2000. [QxMD MEDLINE Link].
Fantl JA, Wyman JF, McClish DK, Harkins SW, Elswick RK, Taylor JR, et al. Efficacy of bladder training in older women with urinary incontinence. JAMA. 1991 Feb 6. 265(5):609-13. [QxMD MEDLINE Link].
Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc. 2000 Apr. 48(4):370-4. [QxMD MEDLINE Link].
Burgio KL, Kraus SR, Johnson TM 2nd, Markland AD, Vaughan CP, Li P, et al. Effectiveness of Combined Behavioral and Drug Therapy for Overactive Bladder Symptoms in Men: A Randomized Clinical Trial. JAMA Intern Med. 2020 Jan 13. [QxMD MEDLINE Link].
Burton JR, Pearce KL, Burgio KL, Engel BT, Whitehead WE. Behavioral training for urinary incontinence in elderly ambulatory patients. J Am Geriatr Soc. 1988 Aug. 36(8):693-8. [QxMD MEDLINE Link].
McDowell BJ, Burgio KL, Dombrowski M, Locher JL, Rodriguez E. An interdisciplinary approach to the assessment and behavioral treatment of urinary incontinence in geriatric outpatients. J Am Geriatr Soc. 1992 Apr. 40(4):370-4. [QxMD MEDLINE Link].
Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ. 2003 Apr 19. 326(7394):841-4. [QxMD MEDLINE Link]. [Full Text].
Lepor H. A comparison of anticholinergic therapies in the treatment of overactive bladder. Rev Urol. 2001 Fall. 3(4):209. [QxMD MEDLINE Link]. [Full Text].
MacDiarmid SA. Overactive bladder: improving the efficacy of anticholinergics by dose escalation. Curr Urol Rep. 2003 Dec. 4(6):446-51. [QxMD MEDLINE Link].
Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006 Oct 18. CD003781. [QxMD MEDLINE Link].
Reynolds WS, McPheeters M, Blume J, Surawicz T, Worley K, Wang L, et al. Comparative Effectiveness of Anticholinergic Therapy for Overactive Bladder in Women: A Systematic Review and Meta-analysis. Obstet Gynecol. 2015 Jun. 125 (6):1423-32. [QxMD MEDLINE Link].
Lee YS, Choo MS, Lee JY, et al. Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial. Int J Clin Pract. 2011 Sep. 65(9):997-1004. [QxMD MEDLINE Link].
Tapp AJ, Cardozo LD, Versi E, Cooper D. The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study. Br J Obstet Gynaecol. 1990 Jun. 97(6):521-6. [QxMD MEDLINE Link].
Roberts RG, Garely AD, Bavendam T. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults. Am J Manag Care. 2005 Jul. 11(4 Suppl):S158-62. [QxMD MEDLINE Link].
Abrams P. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. Expert Opin Pharmacother. 2001 Oct. 2(10):1685-701. [QxMD MEDLINE Link].
Kanofsky JA, Nitti VW. Tolterodine for treatment of overactive bladder. Urol Clin North Am. 2006 Nov. 33(4):447-53, viii. [QxMD MEDLINE Link].
Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003 Jun. 78(6):687-95. [QxMD MEDLINE Link].
Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol. 1999 Mar. 39(3):289-96. [QxMD MEDLINE Link].
Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc. 2002 May. 50(5):799-807. [QxMD MEDLINE Link].
Burgio KL, Goode PS, Johnson TM, et al. Behavioral Versus Drug Treatment for Overactive Bladder in Men: The Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial. J Am Geriatr Soc. 2011 Dec. 59(12):2209-16. [QxMD MEDLINE Link].
Staskin DR. Trospium chloride: Distinct among other anticholinergic agents available for the treatment of overactive bladder. Urol Clin North Am. 2006 Nov. 33(4):465-73, viii. [QxMD MEDLINE Link].
Zinner NR. Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder. Expert Opin Pharmacother. 2005 Jul. 6(8):1409-20. [QxMD MEDLINE Link].
Brunton S, Kuritzky L. Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. Curr Med Res Opin. 2005 Jan. 21(1):71-80. [QxMD MEDLINE Link].
Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int. 2005 Jan. 95(1):81-5. [QxMD MEDLINE Link].
Maniscalco M, Singh-Franco D, Wolowich WR, Torres-Colón R. Solifenacin succinate for the treatment of symptoms of overactive bladder. Clin Ther. 2006 Sep. 28(9):1247-72. [QxMD MEDLINE Link].
Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother. 2006 Mar. 4(1):14-24. [QxMD MEDLINE Link].
Zinner N, Susset J, Gittelman M, Arguinzoniz M, Rekeda L, Haab F. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. Int J Clin Pract. 2006 Jan. 60(1):119-26. [QxMD MEDLINE Link].
Doheny K. FDA OKs First OTC Remedy for Overactive Bladder. Medscape Medical News. Available at http://www.medscape.com/viewarticle/778226. January 25, 2013; Accessed: December 17, 2022.
Herschorn S, Swift S, Guan Z, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int. 2010 Jan. 105(1):58-66. [QxMD MEDLINE Link].
Cardozo L, Amarenco G, Pushkar D, Mikulas J, Drogendijk T, Wright M, et al. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). BJU Int. 2013 May. 111(5):804-10. [QxMD MEDLINE Link].
Vouri SM, Kebodeaux CD, Stranges PM, Teshome BF. Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis. Arch Gerontol Geriatr. 2017 Mar - Apr. 69:77-96. [QxMD MEDLINE Link].
Chapple CR, Yamanishi T, Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology. 2002 Nov. 60(5 Suppl 1):82-8; discussion 88-9. [QxMD MEDLINE Link].
Michel MC, Hegde SS. Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?. Naunyn Schmiedebergs Arch Pharmacol. 2006 Nov. 374(2):79-85. [QxMD MEDLINE Link].
Izett M, Zacche M, Thiagamoorthy G, Robinson D, Cardozo L. Current evidence and emerging drug therapies for overactive bladder. Minerva Ginecol. 2017 Jun. 69 (3):269-285. [QxMD MEDLINE Link].
Myrbetriq (mirabegron) [package insert]. Northbrook, Il: Astellas Pharma. June 2012. Available at [Full Text].
Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a ß(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013 Feb. 63(2):296-305. [QxMD MEDLINE Link].
Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder: Results from a randomised European-Australian phase 3 trial. Eur Urol. November 2012.
De Nunzio C, Brucker B, Bschleipfer T, Cornu JN, Drake MJ, Fusco F, et al. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men. Eur Urol. 2021 Jan 2. [QxMD MEDLINE Link].
Mullen GR, Kaplan SA. Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia. Curr Urol Rep. 2021 Jan 7. 22 (1):5. [QxMD MEDLINE Link].
Chapple CR, Siddiqui E. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia. Expert Rev Clin Pharmacol. 2017 Feb. 10 (2):131-151. [QxMD MEDLINE Link].
Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR. J Urol. 2020 Aug. 204 (2):316-324. [QxMD MEDLINE Link].
Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy From a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR). J Urol. 2020 Dec 28. 101097JU0000000000001574. [QxMD MEDLINE Link].
Rechberger T, Wróbel A. Evaluating vibegron for the treatment of overactive bladder. Expert Opin Pharmacother. 2021 Jan. 22 (1):9-17. [QxMD MEDLINE Link].
Abrams P, Kelleher C, Staskin D, Kay R, Martan A, Mincik I, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World J Urol. 2016 Aug 11. [QxMD MEDLINE Link].
Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, et al. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur Urol. 2016 Jul. 70 (1):136-45. [QxMD MEDLINE Link].
Wada N, Iuchi H, Kita M, Hashizume K, Matsumoto S, Kakizaki H. Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder. Low Urin Tract Symptoms. 2016 Sep. 8 (3):171-6. [QxMD MEDLINE Link].
Abrams P, Kelleher C, Staskin D, Kay R, Martan A, Mincik I, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World J Urol. 2016 Aug 11. [QxMD MEDLINE Link].
FDA Approves Botox To Treat Overactive Bladder. U.S. Food & Drug Administration. Available at https://wayback.archive-it.org/7993/20161022204431/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336101.htm. Jan 18 2013; Accessed: December 17, 2022.
Khan S, Game X, Kalsi V, Gonzales G, Panicker J, Elneil S, et al. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-a for detrusor overactivity in patients with multiple sclerosis. J Urol. 2011 Apr. 185(4):1344-9. [QxMD MEDLINE Link].
Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MF, Menefee SA, et al. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. N Engl J Med. 2012 Nov 8. 367(19):1803-13. [QxMD MEDLINE Link]. [Full Text].
Drake MJ, Nitti VW, Ginsberg DA, Brucker BM, Hepp Z, McCool R, et al. Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. BJU Int. 2017 Nov. 120 (5):611-622. [QxMD MEDLINE Link].
Marcelissen TA, Rahnama'i MS, Snijkers A, Schurch B, De Vries P. Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms. World J Urol. 2016 Jun 7. [QxMD MEDLINE Link].
Noblett K, Benson K, Kreder K. Detailed analysis of adverse events and surgical interventions in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients. Neurourol Urodyn. 2016 Aug 4. [QxMD MEDLINE Link].
Axonics Sacral Neuromodulation (SNM) System for Urinary Control – P180046. U.S. Food & Drug Administration. Available at https://fda.report/PMA/P180046/18/P180046B.pdf. December 13, 2019; Accessed: December 17, 2022.
[Guideline] Poole RL, Dale M, Morgan H, Oladapo T, Brookfield R, Morris R. Axonics Sacral Neuromodulation System for Treating Refractory Overactive Bladder: A NICE Medical Technologies Guidance. Appl Health Econ Health Policy. 2022 May. 20 (3):305-313. [QxMD MEDLINE Link]. [Full Text].
Zhang J, Cheng W, Cai M. Effects of electroacupuncture on overactive bladder refractory to anticholinergics: a single-blind randomised controlled trial. Acupunct Med. 2015 Jun 3. [QxMD MEDLINE Link].
Thiagamoorthy G, Cardozo L, Robinson D. Current and future pharmacotherapy for treating overactive bladder. Expert Opin Pharmacother. 2016 Jul. 17 (10):1317-25. [QxMD MEDLINE Link].
Majima T, Funahashi Y, Takai S, Goins WF, Gotoh M, Tyagi P, et al. Herpes Simplex Virus Vector-Mediated Gene Delivery of Poreless TRPV1 Channels Reduces Bladder Overactivity and Nociception in Rats. Hum Gene Ther. 2015 Nov. 26 (11):734-42. [QxMD MEDLINE Link]. [Full Text].
Robinson D, Hanna-Mitchell A, Rantell A, Thiagamoorthy G, Cardozo L. Are we justified in suggesting change to caffeine, alcohol, and carbonated drink intake in lower urinary tract disease? Report from the ICI-RS 2015. Neurourol Urodyn. 2017 Apr. 36 (4):876-881. [QxMD MEDLINE Link].
Cho A, Eidelberg A, Butler DJ, Danko D, Afshinnekoo E, Mason CE, et al. Efficacy of Daily Intake of Dried Cranberry 500 mg in Women with Overactive Bladder: A Randomized, Double-Blind, Placebo Controlled Study. J Urol. 2021 Feb. 205 (2):507-513. [QxMD MEDLINE Link].
[Guideline] Nambiar AK, Arlandis S, Bø K, et al. European Association of Urology Guidelines on the Diagnosis and Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 1: Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence. Eur Urol. 2022 Jul. 82 (1):49-59. [QxMD MEDLINE Link]. [Full Text].